We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Animal-Free Insulin and Transferrin Growth Supplement Now Available

By LabMedica International staff writers
Posted on 21 Jun 2010
Print article
Investigators working with serum-free culture media are now able to obtain an animal-free media supplement that provides recombinant insulin and transferrin.

ITSE Animal-Free, manufactured by InVitria (Fort Collins, CO, USA), is a recombinant, animal-free media supplement used to improve cell performance. ITSE stands for insulin, transferrin, selenium, and ethanolamine, which are typically required for optimal cell growth in serum-free media.

Ethanolamine is a phospholipid precursor that improves the performance of cells in serum-free media and is required for the growth of some cell types. Insulin has cell-signaling functions and promotes the uptake of glucose and amino acids. Transferrin is a nontoxic carrier of iron and reduces the generation of toxic free-radicals and peroxide. Selenium is required for the activity of glutathione peroxidase, thioredoxin reductase, and other antioxidant enzymes.

The new ITSE supplement is provided as a sterile 100x liquid formula that users should find easy to use and cost-effective compared to other insulin or transferrin supplements, or serum.

"There are no other insulin-transferrin supplements on the market today that provide the confidence of using our completely animal-free, recombinant sources of insulin and transferrin", said Mary Ann Santos, product scientist at InVitria.

Related Links:

InVitria


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Nutating Mixer
Enduro MiniMix
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.